– SWITZERLAND, Zug – CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect John T. Greene and Katherine A. High, M.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year.

“We are very pleased to invite John and Kathy to join our Board of Directors. Together, they will bring significant strategic and operational experience to CRISPR Therapeutics during a critical stage of our company’s growth,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “We look forward to their guidance as we scale the Company and continue to advance our mission of bringing transformative therapies to patients with serious diseases.”

About John Greene

John T. Greene served as Executive Vice President and Chief Financial Officer of Bioverativ from November 2016 to April 2018. Prior to joining Bioverativ, Mr. Greene was the Chief Financial Officer of Willis Group Holdings from June 2014 until January 2016 and was instrumental in its turnaround and subsequent merger with Towers Watson. Before joining Willis, he held senior executive roles at HSBC for eight years, including Chief Financial Officer for HSBC’s largest business unit, the global Retail Bank Wealth Management business. Prior to HSBC, Mr. Greene previously worked for 12 years in various roles at General Electric Company, including as Chief Financial Officer for GE Global Business Finance. Mr. Greene has an undergraduate degree from the State University of New York, and an M.B.A. from Northwestern University’s Kellogg School of Management.

About Dr Katherine High

Katherine A. High, M.D., has been Co-Founder, President and Head of Research & Development and a member of the Board of Directors of Spark Therapeutics, Inc. since September 2014. Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania, an Investigator at Howard Hughes Medical Institute and the Director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia from 2004 to 2014. She completed a five-year term from 2000 to 2005 on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past-president of the American Society of Gene & Cell Therapy. Dr. High holds an A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary M.A. from The University of Pennsylvania.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom.

For more information : http://www.crisprtx.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.